Rituximab: Emerging treatment strategies of immune-mediated glomerular disease

Andrea G. Kattah, Fernando Custodio Fervenza

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The use of monoclonal antibodies in the treatment of malignancy and autoimmune diseases has rapidly expanded in the last decade. Rituximab, a monoclonal antibody to the CD20 antigen on B cells, was first approved by the US FDA in 1997 to treat non-Hodgkin's B-cell lymphoma. It is now used, however, for a variety of diseases in both on- and off-label uses. It was approved by the FDA for use in refractory rheumatoid arthritis in 2007, and in April 2011 it was approved for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitides (including granulomatosis with polyangiitis [Wegener's granulomatosis] and microscopic polyangiitis), based on the promising results of the RAVE trial. Within the field of nephrology, in addition to its use in anti-neutrophil cytoplasmic antibody-associated vasculitides, it is has been used in the treatment of membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis.

Original languageEnglish (US)
Pages (from-to)413-421
Number of pages9
JournalExpert Review of Clinical Immunology
Volume8
Issue number5
DOIs
StatePublished - Jul 2012

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Granulomatosis with Polyangiitis
CD20 Antigens
Monoclonal Antibodies
Microscopic Polyangiitis
Off-Label Use
Membranoproliferative Glomerulonephritis
Membranous Glomerulonephritis
Lupus Nephritis
Nephrology
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Autoimmune Diseases
Rheumatoid Arthritis
B-Lymphocytes
Therapeutics
Rituximab
Neoplasms

Keywords

  • ANCA
  • lupus nephritis
  • membranoproliferative glomerulonephritis
  • membranous nephropathy
  • rituximab
  • vasculitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Rituximab : Emerging treatment strategies of immune-mediated glomerular disease. / Kattah, Andrea G.; Fervenza, Fernando Custodio.

In: Expert Review of Clinical Immunology, Vol. 8, No. 5, 07.2012, p. 413-421.

Research output: Contribution to journalArticle

@article{2334c6fafc664189b35c1860e4076e3a,
title = "Rituximab: Emerging treatment strategies of immune-mediated glomerular disease",
abstract = "The use of monoclonal antibodies in the treatment of malignancy and autoimmune diseases has rapidly expanded in the last decade. Rituximab, a monoclonal antibody to the CD20 antigen on B cells, was first approved by the US FDA in 1997 to treat non-Hodgkin's B-cell lymphoma. It is now used, however, for a variety of diseases in both on- and off-label uses. It was approved by the FDA for use in refractory rheumatoid arthritis in 2007, and in April 2011 it was approved for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitides (including granulomatosis with polyangiitis [Wegener's granulomatosis] and microscopic polyangiitis), based on the promising results of the RAVE trial. Within the field of nephrology, in addition to its use in anti-neutrophil cytoplasmic antibody-associated vasculitides, it is has been used in the treatment of membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis.",
keywords = "ANCA, lupus nephritis, membranoproliferative glomerulonephritis, membranous nephropathy, rituximab, vasculitis",
author = "Kattah, {Andrea G.} and Fervenza, {Fernando Custodio}",
year = "2012",
month = "7",
doi = "10.1586/eci.12.26",
language = "English (US)",
volume = "8",
pages = "413--421",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Rituximab

T2 - Emerging treatment strategies of immune-mediated glomerular disease

AU - Kattah, Andrea G.

AU - Fervenza, Fernando Custodio

PY - 2012/7

Y1 - 2012/7

N2 - The use of monoclonal antibodies in the treatment of malignancy and autoimmune diseases has rapidly expanded in the last decade. Rituximab, a monoclonal antibody to the CD20 antigen on B cells, was first approved by the US FDA in 1997 to treat non-Hodgkin's B-cell lymphoma. It is now used, however, for a variety of diseases in both on- and off-label uses. It was approved by the FDA for use in refractory rheumatoid arthritis in 2007, and in April 2011 it was approved for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitides (including granulomatosis with polyangiitis [Wegener's granulomatosis] and microscopic polyangiitis), based on the promising results of the RAVE trial. Within the field of nephrology, in addition to its use in anti-neutrophil cytoplasmic antibody-associated vasculitides, it is has been used in the treatment of membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis.

AB - The use of monoclonal antibodies in the treatment of malignancy and autoimmune diseases has rapidly expanded in the last decade. Rituximab, a monoclonal antibody to the CD20 antigen on B cells, was first approved by the US FDA in 1997 to treat non-Hodgkin's B-cell lymphoma. It is now used, however, for a variety of diseases in both on- and off-label uses. It was approved by the FDA for use in refractory rheumatoid arthritis in 2007, and in April 2011 it was approved for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitides (including granulomatosis with polyangiitis [Wegener's granulomatosis] and microscopic polyangiitis), based on the promising results of the RAVE trial. Within the field of nephrology, in addition to its use in anti-neutrophil cytoplasmic antibody-associated vasculitides, it is has been used in the treatment of membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis.

KW - ANCA

KW - lupus nephritis

KW - membranoproliferative glomerulonephritis

KW - membranous nephropathy

KW - rituximab

KW - vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84865027447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865027447&partnerID=8YFLogxK

U2 - 10.1586/eci.12.26

DO - 10.1586/eci.12.26

M3 - Article

C2 - 22882216

AN - SCOPUS:84865027447

VL - 8

SP - 413

EP - 421

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 5

ER -